Clinical Trial Update: Gene Therapy for Achromatopsia (CNGA3) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for a gene therapy targeting CNGA3 in achromatopsia completed with results posted in 2022.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achromatopsia

Drugs mentioned

• CNGA3 gene therapy (CNGA3 gene therapy)

Snippet

Sponsor: MeiraGTx UK II Ltd | Conditions: Achromatopsia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-11